We previously established a method to predict the drug metabolism capacity of injured liver based on pharmacokinetic estimation of the amount of cytochrome P450 (CYP) in vivo (PKCYP test), by introducing the apparent liver-to-blood free concentration gradient in vivo (qg) as a parameter. Here we show that the amount of CYP3A2 in CCl4-treated rats can be estimated appropriately by applying the PKCYP test using midazolam (MDZ) as a probe, assuming that the qg value in control rats does not change. We applied the results to predict the clearance of theophylline as a model drug with a physiologically based pharmacokinetic model.
Introduction
More than 75z of drugs are metabolized by hepatic cytochrome P450 (CYP) in humans. A great deal of research has been devoted to estimating the drug metabolism ability in vivo from in vitro data. For instance, Rane and Wilkinson devised a method for estimating the in vivo hepatic clearance from in vitro data obtained with microsomes and hepatocytes. 1, 2) Iwatsubo et al. predicted in vivo hepatic clearance from in vitro data obtained with a CYP expression system. 3) However, methods to predict in vivo clearance in patients from in vitro data are still unsatisfactory in general.
We have established a method for determining drug metabolism capacity based on a physiological pharmacokinetic estimation of the amount of CYP in vivo (PKCYP test) by introducing the apparent liver-toblood free concentration gradient in vivo (qg) as a parameter. [4] [5] [6] [7] [8] We use the total body clearance (CLtot) of a diagnostic probe drug to estimate the amount of CYP in vivo (A-CYPvivo), then the CLtot of a target drug can be predicted based on this value of A-CYPvivo The PKCYP test is expected to be a useful approach for personalized drug therapy, and it is important to conˆrm its validity by means of animal experiments. We have already shown that the amounts of CYP1A2 and CYP2C11 can be reliably estimated with the PKCYP test using acetanilide and tolbutamide as probes, respectively, in rat models. [4] [5] [6] It has been reported that human CYP3A is involved in 50z of all drug metabolism reactions. The amino acid sequence of rat CYP3A2 has 70z identity with human CYP3A, 9) and most of the drugs that are metabolized by human CYP3A are also metabolized by rat CYP3A2. Midazolam (MDZ) is mainly metabolized to two diŠerent metabolites, a-OH MDZ and 4-OH MDZ by CYP3A2. 10) Moreover, it is well known that carbon tetrachloride (CCl4) causes acute liver damage in rats, resulting in a marked reduction in the expression of rat CYP, 11) and CCl4-treated rats are useful as a model of liver function impairment in humans. In this study, rstly, we examined whether the amount of CYP3A2 in CCl4-treated rats can be predicted or not by applying the PKCYP test using MDZ as a probe, assuming that the qg value in control rats does not change. Secondly, we used the results, together with our reported data for CYP1A2, to predict the CLtot of theophylline in CCl4-treated rats (theophylline is mainly metabolized by CYP1A2 and CYP3A2 in rats. 12) ) Thirdly, we simulated the time-course of theophylline concentration in serum with a physiologically-based pharmacokinetic model, and established that the results were in good agreement with the observed values.
Materials and Methods
Materials: Chemicals were obtained from the following sources: midazolam (Dormicam Inj.) was from Yamanouchi Pharmaceutical Co. (Tokyo, Japan); carbon tetrachloride (CCl4) and theophylline were from Wako Pure Chemicals (Osaka, Japan); 1,3-dimethyluric acid (1,3-DMU), 1,3,7-trimethyluric acid (1,3,7-TMU), b-hydroxyethyltheophylline, and rabbit serum were from Sigma Chemical Co. (St. Louis, MO); [8] [9] [10] [11] [12] [13] [14] C]theophylline was from American Radiolabeled Chemicals, Inc. (St. Louis, MO); NADPH was from Oriental Yeast Co. (Tokyo, Japan); and a microsomal preparation from baculovirus-infected insect cells expressing rat CYP3A2 (recombinant rat CYP3A2) and anti-rat CYP3A2 (anti-rat CYP3A2 antibody) were from Daiichi Pure Chemicals Co. (Tokyo, Japan). All other chemicals were of reagent grade or HPLC grade and were used without puriˆcation.
Animals: Male Sprague-Dawley rats, 6 weeks of age, were purchased from Japan SLC, Inc. (Shizuoka, Japan). The rats were pretreated with CCl4 (after an 8-hr fast, 2.5 mL W kg of 20z CCl 4 , dissolved in olive oil, was administered i.p.) to reduce CYP levels and used on the following day. Control animals were used without pretreatment. The animal experiments were performed in accordance with the Guidelines for Animal Experiments of Kyoritsu University of Pharmacy.
In vivo pharmacokinetic studies of MDZ: The control and CCl4-treated rats were given MDZ (10 mg W kg, dissolved in MilliQ water) by intravenous injection. Blood was collected from the jugular vein and centrifuged at 14,000 rpm (MX-150, Tomy Seiko Co., Ltd., Tokyo, Japan) for 10 min at 49 C to obtain serum. Serum was stored at -209 C until analysis.
Determination of serum protein binding of MDZ: MDZ was added to serum to give concentrations of 4, 8, 16, 24 , and 32 mg W mL (total volume, 800 mL), and the samples were incubated for 30 min at 379 C. To separate the free fraction from the protein-bound fraction, 700 mL of each sample was transferred to a centrifuge tube (Centrifree, Amicon, Inc., Beverly, MA) and centrifuged at 1,000×g for 10 min at room temperature. Aliquots of 100 mL of the supernatant (free fraction) or other samples were stored at -209 C until analysis.
Determination of in vitro intrinsic clearance for MDZ by recombinant rat CYP3A2: The assay mixture contained 10 pmol of recombinant rat CYP3A2, 3.26 mM MDZ, 10 mM NADPHW 16.75 mg W mL MgCl2･ 6H2O, and 1 M potassium phosphate buŠer (pH 7.4) in aˆnal volume of 1 mL. The assay mixture without MDZ was preincubated in a shaking bath for 5 min at 379 C, then the reaction was started by the addition of MDZ and incubation was continued in the bath for 0, 10, 20, 30, or 40 min at 379 C. The reaction was halted by the addition of 4 mL of ethyl acetate, and the concentration of remaining MDZ was measured.
Inhibitory eŠect of anti-rat CYP3A2 antibody on MDZ metabolism in liver microsomes: The assay mixture for MDZ metabolism contained 3.26 mM MDZ, 10 mM NADPH W 16.75 mg W mL MgCl2･6H2O, and 1 M potassium phosphate buŠer (pH 7.4) in aˆnal volume of 1 mL. Control or CCl4-treated rat liver microsomes (0.02 or 0.1 mg, respectively) were preincubated with 50 mL of anti-rat CYP3A2 antibody for 30 min at room temperature prior to the measurement of MDZ depletion. Under these conditions, the CYP3A2 activity of all microsomes, irrespective of their origin, was maximally inhibited. Control incubations contained an equivalent amount of preimmune rabbit serum proteins. For the assay, the mixture without MDZ was preincubated in a shaking bath for 5 min at 379 C, then the reaction was started by the addition of MDZ and incubation was continued in the bath for 40 min at 379 C The reaction was halted by the addition of 4 mL of ethyl acetate, and MDZ concentrations were measured. The activity as a percentage of control activity was calculated to determine the contribution ( fCYP) of CYP3A2.
Quantitation of CYP3A2 in liver microsomes of CCl4-treated rats: Liver microsomes were prepared as previously described. 13 Assay of MDZ: MDZ in serum was assayed by HPLC. A mixture of 100 mL of serum, 10 mL of 320 mg W mL phenacetin (internal standard), 1 mL of 1 M sodium phosphate buŠer (pH 7.0), and 2 mL of ethyl acetate was vortexed and centrifuged at 3,000 rpm for 20 min at room temperature. The organic layer was transferred to a fresh tube and evaporated. The extraction with ethyl acetate was performed twice. Each sample was resuspended in 100 mL of HPLC mobile phase, and passed through a 0.45-mmˆlter, and a 60 mL aliquot was subjected to HPLC. A calibration curve was constructed by spiking drug-free rat serum with concentrated MDZ solutions to give concentrations of 0, 4, 8, 16, 24, and 32 mg W mL. Samples were submitted to the extraction procedure described above and a calibration curve was obtained by plotting the peak-area versus drug concentration. The HPLC system consisted of a pump (L-7100, Hitachi, Tokyo, Japan), an autoinjector (L-7200, Hitachi, Tokyo, Japan), a UV detector (L-7400, Hitachi, Tokyo, Japan), an integrator (D-7500, Hitachi, Tokyo, Japan), and a column oven (TU-100, Japan Spectroscopic Co., Ltd., Tokyo, Japan). Separation was achieved on a C18 reversedphase column (250 mm×4.6 mm i.d., particle size 5 mm, Capcell Pak C18 UG120 S-5 mm, Shiseido, Tokyo, Japan) at a column temperature of 409 C. The mobile phase consisted of 30z acetonitrile, 70z 10 mM phosphate buŠer (pH 3.0), at a ‰ow rate of 0.5 mL W min, and the column eluate was monitored at 220 nm. MDZ in the samples from the studies of in vitro MDZ metabolism and inhibition of in vitro MDZ metabolism was also assayed by HPLC. As an internal standard, 100 mL of 4 mg W mL phenacetin, together with 2 mL of 1 M sodium phosphate buŠer (pH 7.0), was added to each sample, followed by vortexing and centrifugation at 3,000 rpm for 20 min at room temperature. The organic layer was transferred to a fresh tube and evaporated. The extraction with ethyl acetate was performed twice. Each sample was resuspended in 100 mL of HPLC mobile phase, and passed through a 0.45-mmˆlter, then a 60 mL aliquot was subjected to HPLC. A calibration curve was constructed with MDZ solutions of 0, 0.05, 0.1, 0.2, 0.4, and 0.8 mg W mL. Samples were submitted to the extraction procedure described above and a calibration curve was obtained by plotting the peak-area versus drug concentration. The HPLC conditions were the same as for the measurement of MDZ in serum.
In vivo pharmacokinetic studies of theophylline: The CCl4-treated rats were given theophylline (1 mg W kg, dissolved in saline) by intravenous injection. Blood was collected from the jugular vein and centrifuged at 14,000 rpm for 10 min at 49 C to obtain serum, which was stored at -209 C until analysis. To determine the urinary elimination of theophylline, the urine was collected at intervals. After measurement of the volume, the urine centrifuged at 700×g for 10 min at 49 C. The supernatant was stored at -209 C until assayed.
Determination of serum protein binding of theophylline: Theophylline was added to serum to give concentrations of 1, 2, 4, 6, 8 and 10 mg W mL (in a total volume of 800 mL). The serum samples were incubated for 30 min at 379 C To separate the free fraction from the protein-bound fraction, 700 mL of each serum sample was transferred to a centrifuge tube (Centrifree, Amicon, Inc., Beverly, MA) and centrifuged at 1,000× g for 10 min at room temperature. Aliquots of 100 mL of the supernatant (free fraction), as well as serum samples containing protein-bound and free drug were stored at -209 C until analysis.
Determination of Michaelis constant and maximal rate of metabolism for theophylline metabolism by recombinant rat CYP3A2: The assay mixture for theophylline metabolism contained 20 pmol of recombinant rat CYP3A2, [8- 14 C]theophylline (12.5, 25, 50, 75, 100 mM), 10 mM NADPH W 16.75 mg W mL MgCl2･ 6H2O, and 250 mM Tris buŠer (pH 8.0) in aˆnal volume of 0.5 mL. The speciˆc activity of [8- 14 C]-theophylline was adjusted to 1887 Bq W nmol by dilution with unlabeled theophylline. The assay mixture without [8- 14 C]theophylline was preincubated in a shaking bath for 10 min at 379 C. The reaction was started by the addition of [8- 14 C]theophylline, and incubation was carried out in a shaking bath for 20 min at 379 C. The reaction was halted by the addition of 100 mL of 20z perchloric acid, and the radioactivity due to theophylline metabolites was measured. The rate of theophylline metabolism was calculated as the sum of the amount of metabolite formation. The Michaelis constant and the maximal rate of metabolism were obtained from a Lineweaver-Burk plot.
Assay of theophylline and its metabolites: The- 7) Assay of the radioactivity of theophylline metabolites in the samples after in vitro theophylline metabolism was done as previously described.
7)
Data analysis: Serum concentration versus time data were analyzed according to model-independent moment analysis. The area under the serum concentration versus time curve was estimated by means of the trapezoidal rule. The last determined serum concentration was extrapolated to inˆnity using the terminal slope of the last two points of the log serum concentrationtime curve. The CLtot, the half-life (t1W 2), and the volume of distribution at the steady-state (Vd,ss) were estimated as described by Yamaoka et al.
14) Data were analyzed using Student's t test for comparison of unpaired means of two sets of data. Analysis of variance was used to compare more than two sets of data. The number of determinations (n) is noted in the table. A p value of 0.05 or less indicates a signiˆcant diŠerence between sets of data.
Results
Comparison of the pharmacokinetics of MDZ in control and CCl4-treated rats: In order to estimate the qg value, the MDZ clearance in control and CCl 4 -treated rats given MDZ (10 mg W kg) by intravenous injection was investigated. Figure 1 shows the blood concentration versus time proˆles obtained. Since the MDZ proˆle suggested linear pharmacokinetics, the CLtot was determined under linear conditions. There were no signiˆcant diŠerences in body weight and microsome content between control and CCl4-treated rats. The pharmacokinetic data are summarized in Table 1 . The CLtot in CCl4-treated rats was only about 25z of that in control rats.
There was no diŠerence in the fCYP of CYP3A2 and the unbound fraction in plasma (fp) of MDZ between the control and CCl4-treated rats. The t1W 2 of MDZ in CCl4-treated rats was about 3-fold longer than that in control rats, and the Vd,ss in CCl4-treated rats was about 80z of that in control rats.
Prediction of liver CYP3A2 content in CCl4-treated rats: The CLtot was used to predict the liver CYP3A2 content in CCl4-treated rats. The intrinsic metabolic clearance (CLint) can be estimated from the CLtot, the fp, and the hepatic blood ‰ow rate (Qh) as follows: CLint＝
The qg value of MDZ in control rats can be estimated according to Eq. (A6) as follows:
where CLint,vitro is the in vitro intrinsic clearance. The qg value of MDZ in control rats based on CL int,vitro obtained from the metabolite formation rate using liver microsomes was estimated to be 10.2 according to Eq.
2) using the parameters listed in Tables 1 and  2 . In this study, we also determined the CLint,vitro from the substrate depletion rate using the CYP3A2 expression system. The CL int,vitro obtained using this method was 3.48×10 -3 mL W min W pmol CYP3A2 ( Table 2) , which was about 2.5-fold larger than the reported value determined from the metabolite production rate using liver microsomes.
15) The qg value of MDZ in control rats based on this CL int,vitro was estimated to be 4.2 according to Eq. (2) using the parameters listed in Tables 1 and 2 . The A-CYPvivo of CYP3A2 in CCl4-treated rats can be predicted according to Eq. (A7) as follows:
The A-CYP vivo of CYP3A2 was predicted to be 18.2 nmol W kg in CCl4-treated rats according to Eq. (3). This value lies within the 95z conˆdence interval of the observed value ( Table 2) .
Comparison of the pharmacokinetics of theophylline in control and CCl 4 -treated rats: The control and CCl4-treated rats were given theophylline (1 mg W kg) by intravenous injection. Since the theophylline proˆle suggested linear pharmacokinetics, the CLtot was determined under linear conditions. The CLtot in CCl4-treated rats was only about 30z of that in control rats. The pharmacokinetic data are summarized in Table 3 . There was no diŠerence in the fp of theophylline between control and CCl4-treated rats. The t1W 2 of theophylline in CCl4-treated rats was about 2-fold longer than that in control rats, and the V d,ss in CCl 4 -treated rats was about 60z of that in control rats. The in vitro Michaelis constant (Km,vitro) and the in vitro maximal rate of metabolism (Vmax,vitro) values obtained using the CYP expression system were 216 mM and 5.99 nmol W min W nmol CYP3A2, respectively ( Table 4) .
Prediction of theophylline clearance in CCl4-treated rats: Previously we reported that theophylline metabolism in the liver is almost entirely mediated by CYP1A2 and CYP3A2. 7) We also reported that the qg value of theophylline estimated from the total hepatic intrinsic clearance was comparable with the qg values estimated from the hepatic intrinsic clearance mediated by CYP1A2 and CYP3A2. 7) Therefore, the qg value of theophylline in control rats was estimated from the sum f The V max,vitro per nmol CYP was calculated using the in vivo amount of CYP, the contribution of each isoform listed in Table 3 and 11.0 g liver W 250 g body weight.
g Ref. 7 . h The CL int,vitro was calculated using the in vivo amount of CYP listed in Table 3 .
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Since the frenal of theophylline in control rats was not zero (Table 3) , the CL int was estimated from the hepatic clearance (CLh), fp, and Qh as follows:
Equation (4) can expressed as follows:
The Vmax,vitro per nmol CYP in liver slices was calculated using the A-CYPvivo, the fCYP listed in Table 3 and a value of 11.0 g liver W 250 g body weight ( Table 4) . The qg values of theophylline in control rats were estimated to be 3.3 and 7.4 using the CYP expression system and liver slices, respectively according to Eq. (6), using the parameters listed in Tables 3 and 4 . Then, the CLint of theophylline in CCl 4 -treated rats was predicted as follows: The parameters listed in Table 4 , predicted A-CYPvivo of CYP1A2 (0.06±0.06 nmol W kg), 8) and predicted A-CYPvivo of CYP3A2 (18.2 nmol W kg), were used here. The predicted CLtot of theophylline was calculated as follows:
where frenal is the renal excretion ( Table 3) . The predicted CL tot in CCl 4 -treated rats were 0.23 and 0.25 mL W min W kg using the CYP expression system and liver slices, respectively. These values were about onethird of the observed value ( Table 3) .
Prediction of time-courses of theophylline concentration in control and CCl 4 -treated rats: The theophylline concentration-time proˆles in serum, following intravenous administration of theophylline at a dose of 1 mgW kg to control and CCl4-treated rats, were estimated using the physiologically based pharmacokinetic model. As shown in Fig. 2 , the predicted serum concentrations agreed well with the observed values.
Discussion
In this study, weˆrstly examined the application of the PKCYP test to CYP3A2 using MDZ as a probe. The amount of CYP3A2 in CCl4-treated rats was reduced to about 7z of that in control rats ( Table 1) . We have already reported that the amounts of CYP1A2 and CYP2C11 in CCl4-treated rats are reduced to about a seventh and quarter of those in control rats, respectively, [4] [5] [6] so it appears that the amount of CYP3A2 in CCl4-treated rats is reduced markedly compared with those of CYP1A2 and CYP2C11.
Although the CLtot of MDZ in CCl4-treated rats was about 25z of that in control rats, the CLint,vivo of MDZ in CCl4-treated rats fell to about 7z of that in control rats. This may re‰ect the decrease in the amount of CYP3A2. Although the qg value of MDZ determined by the substrate depletion approach was smaller than that obtained from the metabolite formation rate ( Table 2) , this might be at least partly due to estimation error of the CLint,vitro of MDZ. In CCl4-treated rats, the predicted A-CYPvivo was within the 95z conˆdence interval of the observed A-CYP vivo ( Table 2 ). It appears that the amount of CYP3A2 can be predicted by using the qg value of MDZ estimated in control rats. The qg value of MDZ was larger than unity as shown in Table 2 . Therefore, the MDZ concentration at the enzyme site may be higher than its free concentration within the hepatic vein, possibly owing to the presence of an uptake system for MDZ in the liver. It has been reported that the uptake of tetraethylammonium (TEA) by human organic cation transporter 1 (hOCT1) is reduced by MDZ, and the amino acid sequence of rat OCT1 (rOCT1) has 78z identity with that of hOCT1. 16, 17) . Thus, reuptake of MDZ by rOCT1 could explain why the qg value of MDZ is larger than unity. We concluded that qg in normal rats could also be applied to rats with hepatic injury. Although further work is needed, the qg value may be a useful parameter for predicting whether a speciˆc drug is concentrated into the liver or not.
Secondly, we examined the application of the PKCYP test to predict the CL tot of theophylline in CCl 4 -treated rats. The values of CLint,vitro of theophylline by CYP3A2 calculated from the Km,vitro and Vmax,vitro values obtained in the expression system was about 2.7-fold greater than the values in liver slices, respectively ( Table 4 ). The qg value of theophylline estimated from the CYP expression system in control rats was 3.3, whereas that determined from the liver slices was 7.4. Since the former value is closer to unity, the in‰uence of the estimation error in CLint,vitro may be smaller. Therefore we considered that a more accurate estimation of the A-CYPvivo would be possible using the qg value obtained with the CYP expression system.
Despite the diŠerence in qg value of theophylline between liver slices and the CYP expression system, the predicted CLtot of theophylline showed good agreement between liver slices and the CYP expression system. However, these predicted values were lower than the observed values. It is considered that some mechanism which compensates for impaired hepatic metabolism may operate in this rat model. In clearance prediction, however, an error of 5-to 10-fold has generally been considered acceptable. Therefore, our PKCYP test approach should be useful for predicting CLtot.
Thirdly, we constructed a physiologically-based pharmacokinetic model of theophylline using the predicted amount of CYP. The simulated values agreed well with the observed values in control and CCl4-treated rats (Fig. 2) , though in CCl4-treated rats, the simulated values tended to be smaller than the observed ones. This was probably due to overestimation of the Vd,ss. The estimated initial concentration of theophylline was smaller than the observed value, possibly as a result of changes in the parameters produced by the liver injury. However, the diŠerence was not signiˆcant.
In conclusion, we have demonstrated that the PKCYP test is applicable to predict the amount of CYP3A2 and the CLtot of theophylline in CCl4-treated rats using MDZ as a probe. We also constructed a physiologically-based pharmacokinetic model for theophylline using the PKCYP approach and showed that it could simulate the observed time course of the drug concentration in serum.
